Phase 2a clinical study of SGX945 in Behçet’s Disease initiating in 2024 PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare…